{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'an imaging biomarker for comparative purposes. The number of new or enlarging hyperintense', 'lesions as detected by T2-weighted MRI has been used as a surrogate marker of efficacy in MS', 'studies (25, 26). Cranial MRI will be performed at the times specified in Section 1.2.', 'In the analysis of secondary endpoints, 4 primary areas will be prioritized. Safety and tolerability', 'for up to 4 years after last dose of alemtuzumab will be assessed using descriptive statistics and', 'evaluated in comparison to the adult data for the treatment of MS using alemtuzumab. Adverse', 'events of special interest will be examined including the subsequent development of infusion-', 'related reactions, events of autoimmunity particularly thyroid, ITP and nephropathies; serious', 'infections. Certain exclusion criteria related to prior disease states associated with such reactions', 'will be emphasized during screening. Routine lab monitoring during the course of the study and', 'followup over 4 years following last infusion is planned.', 'EDSS score changes occurring following Period 1 will be analyzed. The EDSS will be performed', 'by the neurologist at the following visits: Screening, Day-14 to Day -7, Months 4, 8, 12, 15, 18,', '21, and 24/at EOTP, every 6 months in the safety monitoring phase, and at every relapse visit.', 'The EDSS has long been considered the standard for assessing disability in patients with MS', '(27,28).', 'The annualized relapse rate (ARR) will be assessed at Year 2. The annualized relapse rate is', 'widely used and generally accepted as an indicator of the efficacy of drugs to reduce cerebral', 'inflammation in MS studies (27,28).', 'Cognition test scores (BVMT-R and SDMT) will be tested over 2 years. Cognitive decline is', 'recognized as a prevalent and debilitating symptom of multiple sclerosis (MS), especially deficits', 'in episodic memory and processing speed. The change from baseline in cognitive outcomes are to', 'be analysed descriptively. The SDMT is a test of speed that screens for organic cerebral', 'dysfunction and has been validated and used in numerous MS clinical trials (29, 30).', 'The BVMT-R is a test of memory that has been validated in MS and has been used in clinical', 'trials (31). Quality of life measures will be assessed using the validated pediatric Neuro-QOL', 'which will be measured at least every 6 months over 2 years. This measure assesses how disease', \"and health factors affects children's lives (32).\", 'Property of the Sanofi Group - strictly confidential', 'Page 63', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '10', 'STUDY PROCEDURES', 'All the study procedures will be performed following the standard clinical practice of each study', 'center. Refer to the Section 1.2 for more details.', '10.1 VISIT SCHEDULE', 'The visit schedule consists of the following visits:', '10.1.1 Visit 1 Screening visit', 'This visit has to be conducted maximum 28 days prior to M-4 visit.', 'Prior to any assessments, information for the parents/patient regarding the aims and methods of', 'the study, its constraints and risks, and educational material consistent with the risk management', 'plan for alemtuzumab will be reviewed with the parents/patient and a written summary in the', 'form of an informed consent will be given to the parents/patient.', \"The patient/patient's legal guardian must sign the informed consent/assent prior to any action\", 'related to the study.', 'The screening visit will include the following investigations (refer to Section 1.2.1):', 'Recording of medical/surgical history.', 'Physical examination and vital signs: A standard physical examination for clinical and', 'neurological assessments which includes examination of major body systems, height and', 'body weight. Tanner stage will be assessed as well.', 'The following vital signs will be recorded: systolic and diastolic blood pressure', '(millimeters of mercury [mm Hg]), heart rate (beats/minute), respiratory rate', '(breaths/minute), and temperature (degrees Celsius [\u00b0C] or degrees Fahrenheit [\u00b0F]).', 'Demographics (gender, age, and race).', 'Recording of prior MS medications and concomitant medications.', 'Laboratory screening:', '-', 'Hematology (CBC with differential, including platelet count for monitoring for any', 'cytopenia),', '-', 'Chemistry panel: Glucose, creatinine, blood urea nitrogen (BUN), sodium, potassium,', 'chloride, bicarbonate, magnesium, calcium uric acid, aspartate aminotransferase, ALT,', 'gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase, total bilirubin,', 'direct/indirect bilirubin, alkaline phosphatase, inorganic phosphorus, total protein,', 'albumin, globulin, albumin/globulin ratio, triglycerides, cholesterol and creatinine', 'phosphokinase will be assessed,', '-', 'Thyroid function testing (thyroid stimulating hormone),', 'Property of the Sanofi Group - strictly confidential', 'Page 64', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}